The FDA peptide panel vote, scorecard style
Published October 26, 2026. News from July 23 to 24, 2026, as reported by AJMC and others, cited below.
Quick take: an advisory panel backed six of seven peptides, against its own agency staff. The votes are not binding, and nothing is approved.
The scorecard
| Peptide | Result | Reported vote |
|---|---|---|
| BPC-157 | Backed | 8 to 6, 1 abstention |
| KPV | Backed | 8 to 6, 1 abstention |
| TB-500 | Backed | 8 to 6, 1 abstention |
| MOTS-c | Backed | 7 to 5, 2 abstentions |
| Semax | Backed | Tight margin, tally not reported |
| Epitalon | Backed | Tight margin, tally not reported |
| Emideltide | Rejected | 7 to 6 against, 1 abstention |
One report lists slightly different margins for some votes, which is common with fast moving coverage. Check the sources below.
Why it was unusual
AJMC reports that FDA reviewers recommended against all seven, and that briefing materials found the studies, including five BPC-157 trials, too short and small to establish safety or effectiveness for the uses reviewed.
What happens next
- The FDA decides whether to accept each recommendation.
- If it does, it needs notice and comment rulemaking: a proposed rule, public comment, then a final rule.
- Only then could compounding pharmacies legally prepare the substances.
AJMC adds that compounded drugs generally sit outside normal pharmacy coverage, so patients would likely still pay out of pocket.
Background: the full FDA timeline.
Ready to order?
Paste it in the Promo code box in the order summary at checkout, then press Apply. Confirm the discount line before you pay.
Common questions
Did the FDA approve these peptides?
No. The panel's votes are non-binding recommendations.
Which peptide was rejected?
Emideltide, voted down 7 to 6 with one abstention, per AJMC.
What happens next?
The FDA decides, and rulemaking would be needed before pharmacies could compound them.
Sources
- AJMC: FDA panel backs 6 peptides for compounding (Jul 31, 2026)
- Benefits and Pensions Monitor: US advisers voted 8-6 to ease access to peptides Health Canada still bans (Jul 27, 2026)
Summarised in my own words. Read the originals for the full detail.